Authors:
Kappos, L
Comi, G
Panitch, H
Oger, J
Antel, J
Conlon, P
Steinman, L
Citation: L. Kappos et al., Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. (vol 6, pg 1176, 2000), NAT MED, 7(1), 2001, pp. 129-129
Authors:
Kappos, L
Comi, G
Panitch, H
Oger, J
Antel, J
Conlon, P
Steinman, L
Citation: L. Kappos et al., Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial, NAT MED, 6(10), 2000, pp. 1176-1182
Authors:
Hemmer, B
Pinilla, C
Gran, B
Vergelli, M
Ling, N
Conlon, P
McFarland, HF
Houghten, R
Martin, R
Citation: B. Hemmer et al., Contribution of individual amino acids within MHC molecule or antigenic peptide to TCR ligand potency, J IMMUNOL, 164(2), 2000, pp. 861-871
Authors:
Kay-Mugford, P
Benn, SJ
LaMarre, J
Conlon, P
Citation: P. Kay-mugford et al., In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenaseactivity in dogs, AM J VET RE, 61(7), 2000, pp. 802-810
Authors:
Conlon, P
Oksenberg, JR
Zhang, JQ
Steinman, L
Citation: P. Conlon et al., The immunobiology of multiple sclerosis: An autoimmune disease of the central nervous system, NEUROBIOL D, 6(3), 1999, pp. 149-166
Authors:
Pasloske, K
Renaud, R
Burger, J
Conlon, P
Citation: K. Pasloske et al., Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs, J VET PHARM, 22(5), 1999, pp. 314-319